Results 41 to 50 of about 52,949 (209)

Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer

Journal of Pharmacological Sciences, 2017
Blockade of EGFR with reversible EGFR tyrosine kinase inhibitors (TKIs) is considered the frontline strategy for advanced NSCLC with EGFR mutations. However, acquired resistance to EGFR-TKI has been observed, resulting in disease progression and limited ...
Honggang Wang, Zhenghua Fei, Hao Jiang
doaj   +1 more source

Imaging Patterns and Prognosis of Patients with Gefitinib-Related Interstitial Lung Disease

, 2012
Purpose: We aimed to summarize the imaging findings of 25 patients with gefitinib-related interstitial lung disease ( ILD), and identify the factors related to prognosis of gefitinib-related ILD in patients with non -small-cell-lung cancer. Materials and
YUAN, MEI-KANG;CHANG, CHENG-YU;CHANG, SHIH-CHIEH;CHANG, SHU-JU;TANG, KAO-CHUN;WEI, YU-FENG;CHEN, CHENG-YU;YU, CHONG-JEN, 苑梅剛;張晟瑜;張仕杰;張淑如;唐高駿;魏裕峰;陳正昱;余忠仁   +1 more
core   +1 more source

BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib

JTO Clinical and Research Reports, 2021
Introduction: DNA repair capacity, as exemplified by BRCA1 gene expression, is related with outcome to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant NSCLC. Olaparib, a PARP inhibitor, reduces BRCA1 expression.
Niki Karachaliou, MD, PhD, Oscar Arrieta, MD, Ana Giménez-Capitán, BSc, Erika Aldeguer, BSc, Ana Drozdowskyj, PhD, Imane Chaib, PhD, Noemí Reguart, MD, PhD, Rosario Garcia-Campelo, MD, Jing-Hua Chen, MD, Miguel Angel Molina-Vila, PhD, Rafael Rosell, MD, PhD   +10 more
doaj   +1 more source

Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells

, 2014
Objectives: Gefitinib, a quinazoline-derived tyrosine kinase inhibitor, has anti-tumor activity in vivo and in vitro. Human MutS homologue-2 (MSH2) plays a central role in promoting genetic stability by correcting DNA replication errors.
Ko, Jen-Chung;Chiu, Hsien-Chun;Wo, Ting-Yu;Huang, Yi-Jhen;Tseng, Sheng-Chieh;Huang, Yu-Ching;Chen, Huang-Jen;Syu, Jhan-Jhang;Chen, Chien-Yu;Jian, Yun-Ting;Jian, Yi-Jun;Lin, Yun-Wei
core   +1 more source

EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer

Technology in Cancer Research & Treatment
Background: To evaluate the efficacy and safety of allogenic CD8 + natural killer T (CD8+ NKT) immunotherapy combined with gefitinib in the treatment of advanced or metastatic EGFR mutant non-small cell lung cancer (NSCLC).
Fei Ye BS, Xiao Yuan SM, Wanjun Yu MM, Yali Ma MM, Chaoming Mao MD, Xiaoqin Li MD, Jian Li MD, Chunhua Dai MD, Fenhong Qian MD, Junrong Li MD, Xiujuan Fan BS, Yuepeng Zhou MM, Dongfang Dai MD, Deqiang Wang MD, Deyu Chen MD, Sheng Xia MD, Minghui Zhang MD   +16 more
doaj   +1 more source

m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression

Cell Death and Disease, 2022
Gefitinib has been widely applied for the treatment of lung adenocarcinoma (LUAD). However, the long-term application of gefitinib usually leads to acquired drug resistance in tumour patients, resulting in clinical treatment failure. Small nucleolar host
Heng Zhang, Shao-Qiang Wang, Li Wang, Hang Lin, Jie-Bo Zhu, Ri Chen, Lin-Feng Li, Yuan-Da Cheng, Chao-Jun Duan, Chun-Fang Zhang   +9 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib

Frontiers in Oncology, 2020
Gefitinib resistance in triple negative breast cancer (TNBC) is a growing important concern. Glutathione peroxidase 4 (GPX4) is a main regulator of ferroptosis, which is pivotal for TNBC cell growth. We investigated GPX4-mediated ferroptosis in gefitinib
Xiang Song, Xinzhao Wang, Zhaoyun Liu, Zhiyong Yu   +3 more
doaj   +1 more source

Angiotensin II type 1 receptor blockade attenuates gefitinib-induced cardiac hypertrophy via adjusting angiotensin II-mediated oxidative stress and JNK/P38 MAPK pathway in a rat model

Saudi Pharmaceutical Journal, 2022
Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR), used for the treatment of advanced or metastatic non-small cell lung cancer.
Wael A. Alanazi, Hussain N. Alhamami, Metab Alharbi, Khalid Alhazzani, Abdulrahman S. Alanazi, Sary Alsanea, Nemat Ali, Abdullah F. Alasmari, Ahmed Z. Alanazi, Moureq R. Alotaibi, Mohammed Alswayyed   +10 more
doaj   +1 more source

Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation

Advanced Science, EarlyView.
Dynamic supramolecular assembly reshapes targeted protein degradation by coordinating modular degrader construction, delivery, functional integration, and intracellular assembly or activation across proteasomal, endosomal–lysosomal, and autophagy–lysosomal pathways.
Kongjun Liu, Xue Yuan, Yan Zhou, Rui Yuan, Shaocheng Xie, Yong Chen, Peiyi Wang, Jianmei Gao, Qihai Gong   +8 more
wiley   +1 more source